CY1111183T1 - Νεες θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο) φαινυλο]πιπεραζινης ως ενωσης με συνδυασμενη δραστικοτητα 5-ητ3 και 5-ητ1α παρακρατησης σεροτονινης για τον πονο ή τα καταλοιπα συμπτωματα στην καταθλιψηπου σχετιζονται με τον υπνο και την αντιληψη - Google Patents

Νεες θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο) φαινυλο]πιπεραζινης ως ενωσης με συνδυασμενη δραστικοτητα 5-ητ3 και 5-ητ1α παρακρατησης σεροτονινης για τον πονο ή τα καταλοιπα συμπτωματα στην καταθλιψηπου σχετιζονται με τον υπνο και την αντιληψη

Info

Publication number
CY1111183T1
CY1111183T1 CY20111100166T CY111100166T CY1111183T1 CY 1111183 T1 CY1111183 T1 CY 1111183T1 CY 20111100166 T CY20111100166 T CY 20111100166T CY 111100166 T CY111100166 T CY 111100166T CY 1111183 T1 CY1111183 T1 CY 1111183T1
Authority
CY
Cyprus
Prior art keywords
piperazine
pain
phenyl
katathlipsipou
dimethylofainylosoulfanylo
Prior art date
Application number
CY20111100166T
Other languages
English (en)
Inventor
Nicholas Moore
Tine Bryan Stensbøl
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39564604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111183(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1111183T1 publication Critical patent/CY1111183T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η χρήση 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζίνης για τη θεραπεία του πόνου και των καταλοίπων συμπτωμάτων στην κατάθλιψη παρέχεται.
CY20111100166T 2007-03-20 2011-02-11 Νεες θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο) φαινυλο]πιπεραζινης ως ενωσης με συνδυασμενη δραστικοτητα 5-ητ3 και 5-ητ1α παρακρατησης σεροτονινης για τον πονο ή τα καταλοιπα συμπτωματα στην καταθλιψηπου σχετιζονται με τον υπνο και την αντιληψη CY1111183T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700427 2007-03-20
EP08715617A EP2142193B1 (en) 2007-03-20 2008-03-14 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition

Publications (1)

Publication Number Publication Date
CY1111183T1 true CY1111183T1 (el) 2015-06-11

Family

ID=39564604

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100166T CY1111183T1 (el) 2007-03-20 2011-02-11 Νεες θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο) φαινυλο]πιπεραζινης ως ενωσης με συνδυασμενη δραστικοτητα 5-ητ3 και 5-ητ1α παρακρατησης σεροτονινης για τον πονο ή τα καταλοιπα συμπτωματα στην καταθλιψηπου σχετιζονται με τον υπνο και την αντιληψη

Country Status (29)

Country Link
US (1) US8664225B2 (el)
EP (1) EP2142193B1 (el)
JP (1) JP5371790B2 (el)
KR (1) KR101459168B1 (el)
CN (2) CN101636161A (el)
AR (1) AR065797A1 (el)
AT (1) ATE495745T1 (el)
AU (1) AU2008228638B2 (el)
BR (1) BRPI0808941A2 (el)
CA (1) CA2684571C (el)
CL (1) CL2008000795A1 (el)
CO (1) CO6220962A2 (el)
CY (1) CY1111183T1 (el)
DE (1) DE602008004643D1 (el)
DK (1) DK2142193T3 (el)
EA (1) EA017058B1 (el)
ES (1) ES2355434T3 (el)
HR (1) HRP20110058T1 (el)
IL (2) IL200956A (el)
MX (1) MX2009009672A (el)
MY (1) MY150448A (el)
NZ (1) NZ579721A (el)
PL (1) PL2142193T3 (el)
PT (1) PT2142193E (el)
RS (1) RS51560B (el)
SI (1) SI2142193T1 (el)
TW (1) TW200848411A (el)
UA (1) UA97392C2 (el)
WO (1) WO2008113359A2 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2044043T5 (pl) * 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
PL2421534T3 (pl) * 2009-04-24 2014-12-31 H Lundbeck As Ciekłe preparaty soli 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
CN102639117A (zh) 2009-08-24 2012-08-15 H.隆德贝克有限公司 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物
BR112012027794A2 (pt) * 2010-04-30 2016-08-02 Takeda Pharmaceutical tablete entérico
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
WO2014044721A1 (en) * 2012-09-19 2014-03-27 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
US20160200698A1 (en) * 2013-09-12 2016-07-14 Hangzhou Pushai Pharmaceutical Technology Co., Ltd Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
EP3082815B1 (en) 2013-12-20 2018-10-03 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN106103418A (zh) * 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105198837B (zh) * 2014-06-09 2018-05-04 上海医药工业研究院 一种沃替西汀氢溴酸盐晶体及其制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN106279066A (zh) * 2015-05-22 2017-01-04 天津药物研究院有限公司 一种氢溴酸沃替西汀晶体的纯化方法
CN106556663B (zh) * 2015-09-30 2018-05-29 成都弘达药业有限公司 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪或其盐的检测方法
CN109311833B (zh) 2016-06-16 2022-11-04 广东东阳光药业有限公司 二芳基硫醚哌嗪类化合物及其制备方法和用途
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
HRP20220108T1 (hr) * 2017-04-25 2022-04-15 H. Lundbeck A/S Postupak za proizvodnju vortioksetina hbr alfa-oblika
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
PL2044043T5 (pl) * 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych

Also Published As

Publication number Publication date
JP2010521501A (ja) 2010-06-24
CO6220962A2 (es) 2010-11-19
US20110009422A1 (en) 2011-01-13
ATE495745T1 (de) 2011-02-15
EA200970870A1 (ru) 2010-04-30
AR065797A1 (es) 2009-07-01
KR20090125251A (ko) 2009-12-04
IL200956A0 (en) 2010-05-17
TW200848411A (en) 2008-12-16
MX2009009672A (es) 2009-12-15
EP2142193B1 (en) 2011-01-19
IL200956A (en) 2015-05-31
PT2142193E (pt) 2011-02-02
CN103948597A (zh) 2014-07-30
RS51560B (en) 2011-06-30
CN101636161A (zh) 2010-01-27
MY150448A (en) 2014-01-30
US8664225B2 (en) 2014-03-04
EP2142193A2 (en) 2010-01-13
CA2684571A1 (en) 2008-09-25
PL2142193T3 (pl) 2011-04-29
DK2142193T3 (da) 2011-03-28
EA017058B1 (ru) 2012-09-28
IL238068A0 (en) 2015-05-31
AU2008228638B2 (en) 2012-09-20
CA2684571C (en) 2012-08-14
HRP20110058T1 (hr) 2011-03-31
JP5371790B2 (ja) 2013-12-18
ES2355434T3 (es) 2011-03-25
KR101459168B1 (ko) 2014-11-07
CL2008000795A1 (es) 2008-09-26
AU2008228638A1 (en) 2008-09-25
BRPI0808941A2 (pt) 2014-08-19
SI2142193T1 (sl) 2011-03-31
WO2008113359A3 (en) 2008-11-13
DE602008004643D1 (de) 2011-03-03
NZ579721A (en) 2011-07-29
WO2008113359A2 (en) 2008-09-25
UA97392C2 (ru) 2012-02-10

Similar Documents

Publication Publication Date Title
CY1111183T1 (el) Νεες θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο) φαινυλο]πιπεραζινης ως ενωσης με συνδυασμενη δραστικοτητα 5-ητ3 και 5-ητ1α παρακρατησης σεροτονινης για τον πονο ή τα καταλοιπα συμπτωματα στην καταθλιψηπου σχετιζονται με τον υπνο και την αντιληψη
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
NI201000093A (es) Toalla para llevar puesta
NO20090229L (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2007001318A1 (es) Uso de flibanserina,opcionalmente como base libre,sal hidrato o solvato de ella,para preparar un medicamento util en el tratamiento de trastornos de deseo sexual en mujeres.
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
UY33276A (es) Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso
AR065798A1 (es) Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TW200833342A (en) 2-substituted pyrimidines I in therapy
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
CO6311076A2 (es) Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente
CO6680652A2 (es) Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina
SV2010003578A (es) Oxazolidinonas para el tratamiento y profilaxis de la insuficiencia cardiaca
UY31499A1 (es) Nuevo uso medico de las sales de propionato 3- (2,2,2-trimetilhydrazinio) en el trtamiento de la enfermedad cardiaca isquemica
DK2155179T3 (da) Axomadol til smertebehandling arthrose
CY1118117T1 (el) Νεα αμινο-πυρρολινικα παραγωγα και η χρηση τους στην προληψη ή και τη θεραπεια του μεταβολικου συνδρομου
DK1904511T3 (da) Homogemcitabin
PA8805901A1 (es) Nuevo uso medico de las sales de propionato de 3-(2,2,2-trimetilhidrazinio) para la profilaxis y el tratamiento de la aterosclerosis
BRPI0910058A2 (pt) agentes adrenérgicos alfa 2 de subtipo seletivo e métodos para uso dos mesmos